Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy

Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. In 2015, an estimated 60,600 new cases were diagnosed in Mainland China, accounting for 40% of all cases worldwide [1]. The Tumor-Node-Metastasis (TNM) staging system of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) is the most important tool for guiding treatment strategies in clinical practice. Radiotherapy alone is the recommended approach for stage I NPC, and concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy is the first choice for locoregionally advanced NPC (LANPC; stage III-IV, without distant metastasis) [2,3].

http://ift.tt/2s91AC7